| ²é¿´: 216 | »Ø¸´: 0 | |||
linlin7
|
[½»Á÷]
ÕûºÏ»úÖÆÐÔ½¨Ä£ÓëÄ£ÄâÖúÁ¦ÖƼÁ¿ª·¢Óë·¨¹æÆÀ¹À
|
|
ÕûºÏ»úÖÆÐÔ½¨Ä£ÓëÄ£ÄâÖúÁ¦ÖƼÁ¿ª·¢Óë·¨¹æÆÀ¹À ÕûºÏ»úÖÆÐÔ½¨Ä£ÓëÄ£ÄâÖúÁ¦ÖƼÁ¿ª·¢Óë·¨¹æÆÀ¹À Incorporating Mechanistic Modeling & Simulation to Assist with Formulation Development and Regulatory Evaluations µ¼¶Á 5ÔÂ19ÈÕ£¬ÃÀ¹úFDA·ÂÖÆÒ©²¿¾Ù°ì¡°¿Ú·þ½¨Ä£ÓëÄ£ÄâÔÚÖÆ¼Á¿ª·¢ÓëBEÆÀ¼ÛÓ¦ÓÃÅàѵ°à¡±£¬ÑûÇëSimulations Plus¹«Ë¾½¨Ä£ÓëÄ£Äⲿ×ܼàViera Lukacova½²½âÁË»úÖÆÐÔÄ£ÐÍÔÚÖÆ¼Á¿ª·¢Óë·¨¹æÆÀ¹ÀÖеÄÓ¦ÓᣠViera Lukacova²©Ê¿µÄÄÚÈÝ·ÖΪ4¸ö²¿·Ö£º 1£©ÎªÊ²Ã´Òª×ö½¨Ä£ÓëÄ£Ä⣿ 2£©»úÖÆÐÔÄ£ÄâÄ£Ðͼò½é£ºÔ¤²âÌåÄÚÎüÊÕ¼°PK 3£©Ó¦ÓÃÓÚ·ÂÖÆÒ©²úÆ·µÄ¿ª·¢£º -²úÉúÌåÄÚÍâÏà¹ØÐÔIVIVCs -ÐéÄâBEÊÔÑéÓ뽨Á¢ÈܳöÖÊÁ¿¹æ·¶ -Àí½âʳÎïЧӦ 4£©Ò»¸ö³É¹¦ÉúÎïµÈЧÐÔÊÔÑé»íÃâµÄʵÀý 5ÔÂ19ÈÕFDA workshopµÄÄ¿µÄ£º 1£©·ÖÏíFDAÏÖ½ñÔÚ»ùÓÚ»úÖÆµÄÎüÊÕÄ£Ðͽ¨Ä£ÓëÄ£ÄâÔÚ·¨¹æ»î¶¯ÖеÄÓ¦ÓþÑ飻 2£©ÌÖÂÛµ±Ï¼°½«À´ÈçºÎÔËÓûùÓÚ»úÖÆµÄÎüÊÕ½¨Ä£ÓëÄ£ÄâÄ£ÐÍÔÚ¿ª·¢BEµÄ¿Ú·þÒ©Î¼°·¨¹æ¼à¹Ü£» 3£©´Ó¹«ÖÚ»ñµÃ¹ØÓÚÔÚ¿ª·¢BEµÄ¿Ú·þÒ©Îï¼°BEÉóÆÀʱµÄ¼¼ÊõÖ§³Ö£ººÎʱ¡¢ºÎ´¦¡¢ÔõÑùÔËÓûùÓÚ»úÖÆµÄÎüÊÕ½¨Ä£ÓëÄ£Äâ¡£ The purpose of the workshop is to: 1. Share FDA's current experiences on the application of mechanism-based absorption modeling and simulation in regulatory activities; 2. Discuss the current and future utility of mechanism-based absorption modeling and simulation in development of bioequivalent oral drug products and regulatory reviews; 3. Obtain input from the public on when, where, and how mechanism-based absorption modeling and simulation should be applied in development of bioequivalent oral drug products and review of bioequivalence. |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸±±»¯Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085601²ÄÁϹ¤³ÌÕÒµ÷¼Á
ÒѾÓÐ6È˻ظ´
318Ò»Ö¾Ô¸¼ªÁÖ´óѧÉúÎïÓëÒ½Ò© Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
һ־Ը˫һÁ÷»úе285·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ£¬080500ѧ˶£¬×Ü·Ö317·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤£¬×Ü·Ö321£¬Ó¢Ò»Êý¶þ£¬ÇóÀÏʦÊÕÁô¡£
ÒѾÓÐ8È˻ظ´
375Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ÄϾ©´óѧ»¯Ñ§µ÷¼Á
ÒѾÓÐ7È˻ظ´
070300»¯Ñ§354Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´















»Ø¸´´ËÂ¥
10